Castle Biosciences to Participate in Upcoming Investor Conferences - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2025 Global Healthcare Conference ...
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences will participate in three investor conferences in September ...
Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday - Arteris ( NASDAQ:AIP ) , AECOM ( NYSE:ACM )
U.S. stocks were lower, with the Dow Jones index gaining around 100 points on Tuesday. Shares of Sterling Infrastructure, Inc. STRL rose sharply during Tuesday's session after the company reported better-than-expected quarterly financial results and raised its FY25 guidance.
Castle ( CSTL ) Q2 Revenue Tops Estimates
Castle Biosciences ( NASDAQ:CSTL ) , a developer of diagnostic tests supporting personalized treatment decisions in dermatology and gastroenterology, reported its second quarter 2025 results on August 4, 2025. The company significantly outperformed Wall Street expectations in Q2 2025, with GAAP ...
Castle Biosciences, Inc. ( CSTL ) Q2 Earnings and Revenues Surpass Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of +129.41% and +16.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for August 1st
CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.
TG Therapeutics ( TGTX ) Earnings Expected to Grow: What to Know Ahead of Q2 Release
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Castle Biosciences' executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference Aug. 12, 2025 at 12:30pm ET ...
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, July 29, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45th Annual Growth ...
Earnings Preview: Castle Biosciences, Inc. ( CSTL ) Q2 Earnings Expected to Decline
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
Castle announced that its chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal.
FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test
Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture
Castle Biosciences announced that it has earned multiple awards through the 2025 Top Workplaces program recognizing its strong company culture.
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
Castle Biosciences will release Q2 2025 financial results and host conference call on Monday, Aug. 4, 2025 at 4:30 p.m. ET ...
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, July 14, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on ...
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
FRIENDSWOOD, Texas, June 19, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. ( Nasdaq: CSTL ) , a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock ...
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
Castle Biosciences, Inc. today announced that it has entered entered into a collaboration and license agreement with SciBase Holding AB.
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, June 11, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc.
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
Derek Maetzold, CEO of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during BIO 2025.
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, May 29, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc.
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
Castle will present new data aimed at enhancing the clinical management of patients with cutaneous melanoma and uveal melanoma at ASCO 2025.
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
Castle's executive management will present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 am ET ...
Castle Biosciences Celebrates Skin Cancer Awareness Month
Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month ...
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Quest Diagnostics ( NYSE:DGX ) , Castle Biosciences ( NASDAQ:CSTL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham cut ON Semiconductor Corporation ON price target from $57 to $50.
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Castle Biosciences ( NASDAQ:CSTL ) , EverQuote ( NASDAQ:EVER )
U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. Shares of Ichor Holdings, Ltd. ICHR fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results and issued second-quarter guidance ...
Castle Biosciences, Inc. ( CSTL ) Reports Q1 Loss, Tops Revenue Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of -150% and 9.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences to Acquire Previse - Castle Biosciences ( NASDAQ:CSTL )
Expected to complement Castle's current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc.
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer - Castle Biosciences ( NASDAQ:CSTL )
Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, "The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC" FRIENDSWOOD, Texas, May 02, 2025 ( GLOBE NEWSWIRE ) -- ...
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
Castle Biosciences will share new data on its TissueCypher test for patients with Barrett's esophagus at DDW 2025.
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.
GSK ( GSK ) Q1 Earnings Surpass Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 4.63% and 0.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, April 28, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders.
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, April 25, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc.
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
Castle Biosciences will share new data intended to improve the care of patients with cutaneous and uveal melanoma at the AACR Annual Meeting 2025.
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, April 14, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on ...
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025.
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle is supporting key educational programs and initiatives throughout April in recognition of Esophageal Cancer Awareness Month.
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups - Castle Biosciences ( NASDAQ:CSTL )
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma ( SCC ) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital ( BWH ) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk ...
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
Castle Biosciences will share new data on DecisionDx-SCC and DecisionDx-Melanoma at the NCCN 2025 Annual Conference.
Castle Biosciences, Inc. ( CSTL ) Surpasses Q4 Earnings and Revenue Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 190.91% and 0.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.
Castle Biosciences, Inc. ( CSTL ) Reports Next Week: Wall Street Expects Earnings Growth
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 50.79% Upside in Castle Biosciences ( CSTL ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.8% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.
Zoetis Stock Down Despite Q4 Earnings & Revenues Beat Estimates
ZTS stock falls despite better-than-expected fourth-quarter results due to a weak 2025 outlook.
Surging Earnings Estimates Signal Upside for Castle Biosciences ( CSTL ) Stock
Castle Biosciences (CSTL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Castle Biosciences ( CSTL ) Upgraded to Buy: Here's Why
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Adaptive Biotechnologies ( ADPT ) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
Mettler-Toledo Q4 Earnings Top Estimates, Sales Up Y/Y, Shares Rise
MTD's fourth-quarter 2024 results reflect strong growth in the Laboratory business. However, softness in the Food Retail business reflects weaker demand.
